cerecor-logo-final.png
Cerecor to Participate in Upcoming Investor Conferences
May 17, 2021 07:00 ET | Cerecor Inc.
ROCKVILLE, Md. and CHESTERBROOK, Pa., May 17, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization...
cerecor-logo-final.png
Cerecor Reports First Quarter 2021 Financial Results and Provides Business Updates
May 13, 2021 07:00 ET | Cerecor Inc.
Announced CERC-002 received Fast Track Designation from the U.S. Food and Drug Administration, following positive Phase 2 clinical trial for the treatment of patients hospitalized with COVID-19...
cerecor-logo-final.png
FDA Grants Fast Track Designation to CERC-002 for Treatment of Hospitalized Patients with COVID-19
May 11, 2021 07:00 ET | Cerecor Inc.
ROCKVILLE, Md. and CHESTERBROOK, Pa., May 11, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of...
cerecor-logo-final.png
Cerecor Doses First Patient in a Phase 1b Proof-of-Concept Clinical Trial of CERC-007 for the Treatment of Adult Onset Still’s Disease
May 05, 2021 07:00 ET | Cerecor Inc.
Initial data anticipated in the third quarter of 2021Top-line data from the ongoing Phase 1b proof of concept clinical trial in relapsed or refractory multiple myeloma patients anticipated in the...
cerecor-logo-final.png
Cerecor Announces New Worldwide License Agreement with Kyowa Kirin for Anti-LIGHT Antibody CERC-002
March 29, 2021 07:00 ET | Cerecor Inc.
Expanded agreement for exclusive, world-wide rights to develop, manufacture and commercialize CERC-002 for all indications including severe pediatric onset inflammatory bowel disease and ARDS...
cerecor-logo-final.png
Cerecor Reports 2020 Financial Results and Provides Business Updates
March 08, 2021 16:01 ET | Cerecor Inc.
 •Announced CERC-002 significantly reduced respiratory failure and mortality in Phase 2 clinical trial in patients hospitalized with COVID-19 ARDS •Improved financial position with $18.9M of cash on...
cerecor-logo-final.png
Cerecor to Present at Upcoming Investor Conferences
March 04, 2021 07:00 ET | Cerecor Inc.
ROCKVILLE, Md. and CHESTERBROOK, Pa., March 04, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and...
cerecor-logo-final.png
Cerecor Announces CERC-002 Significantly Reduced Respiratory Failure and Mortality in Phase 2 Clinical Trial in Patients Hospitalized with COVID-19 ARDS
March 02, 2021 07:00 ET | Cerecor Inc.
Final analysis inclusive of the 60-day safety update in the randomized placebo-controlled study demonstrated CERC-002 was statistically significant in reducing respiratory failure and mortality at Day...
cerecor-logo-final.png
Cerecor Appoints Schond L. Greenway as Chief Financial Officer
March 01, 2021 07:00 ET | Cerecor Inc.
ROCKVILLE, Md. and CHESTERBROOK, Pa., March 01, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ:CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization...
cerecor-logo-final.png
Cerecor Announces Fast Track Designation for CERC-803 for the Treatment of Leukocyte Adhesion Deficiency Type II
February 02, 2021 07:00 ET | Cerecor Inc.
ROCKVILLE, Md., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare...